BSX Stock Analysis — Boston Scientific
Sector: Healthcare
AI Verdict
BSX trades at 17.7x next year's earnings with 37.5% EPS growth expected—cheap for the growth on offer if its entrenched device portfolio keeps competitors at bay.
Competitive Moat
Boston Scientific specializes in minimally invasive medical devices for cardiology, electrophysiology, and other high-barrier therapeutic areas where FDA approvals and physician adoption create significant switching costs. Its breadth of proprietary devices and entrenched hospital relationships make it hard for new entrants to displace.
Summary
A sharp expected rebound in earnings (+37.5% EPS growth) has made BSX's valuation look much cheaper than peers after a -43.06% one-year slump.
Where It Stands
BSX is down -43.06% over the past year, trades at 17.7x forward earnings versus a healthcare sector median of 22x, and its RSI of 41.2 signals the stock is in a cooling, not oversold, zone.
Key Metrics
- RSI: 41.2 — Neutral
- Trailing P/E: 24.4x
- Forward P/E: 17.7x
- PEG Ratio: 0.60
- Earnings Growth: +0.4%
- Revenue Growth: +0.2%
- Market Cap: $86.5B
- 1-Year Return: -43.06%
- 52-Week High: $109.50
- 52-Week Low: $59.38
Analyst Consensus
38 Buy · 3 Hold · 0 Sell (41 analysts)
Bull Case
With analysts projecting 37.5% EPS growth and a forward P/E of just 17.7x, you're paying a below-average price for above-average growth in a sector where the median P/E is 22x.
Bear Case
If the forward P/E reverts to the sector median of 22x, there's little room for multiple expansion, and an RSI of 41.2 suggests the stock could drift sideways if growth stalls.
Catalyst to Watch
Watch for FDA approvals or major clinical trial readouts, as positive results could validate the 37.5% EPS growth forecast and drive a re-rating.